Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Nebraska: - Nebraska Cancer Specialists St Francis Grand Island — Grand Island, Nebraska
- Nebraska Cancer Specialists — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in Nebraska: - Oncology Hematology West, Pc Dba Nebraska Cancer Specialists — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Nebraska: - Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
- University Of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting Industry
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-H…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06806033
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Nebraska: - Fred and Pamela Buffett Cancer Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor: CellCentric Ltd.
NCT ID: NCT04068597
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting Academic/Other
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do…
Sponsor: University of Nebraska
NCT ID: NCT07292272
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Nebraska: - Oncology Hematology West, PC dba Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1 Recruiting Industry
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
Sponsor: Incyte Corporation
NCT ID: NCT07195916
Sites in Nebraska: - The University of Nebraska Medical Center — Omaha, Nebraska
Phase 1 Recruiting Industry
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is …
Sponsor: AbbVie
NCT ID: NCT05512390
Sites in Nebraska: - University of Nebraska Medical Center /ID# 246715 — Omaha, Nebraska
Phase 1 Recruiting Industry
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leu…
Sponsor: Umoja Biopharma
NCT ID: NCT06528301
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nebraska: - CHI Health Saint Francis — Grand Island, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
- Alegent Health Immanuel Medical Center — Omaha, Nebraska
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Nebraska: - CHI Health Good Samaritan — Kearney, Nebraska
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 4 Recruiting Industry
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed in…
Sponsor: Eli Lilly and Company
NCT ID: NCT06876649
Sites in Nebraska: - University Of Nebraska Medical Center — Omaha, Nebraska
Phase 4 Recruiting Industry
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator st…
Sponsor: Eli Lilly and Company
NCT ID: NCT06876662
Sites in Nebraska: - University Of Nebraska Medical Center — Omaha, Nebraska
NA Recruiting Academic/Other
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk fo…
Sponsor: University of Nebraska
NCT ID: NCT04898790
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska